Nura Bio
CompanyUnited States
Nura Bio develops 2 assets, the furthest in phase 1 (NB-4746 in ALS). Mostly small molecule acting on NAD+ metabolism and SARM1; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 1
- Raised
- US$214.8m
- 1
- Trial
- 0
- Signals
Pipeline
2Inhibits SARM1.
Phase 1, Small molecule, NAD+ metabolism, SARM1, ALS, amyotrophic lateral sclerosis
Covalent irreversible allosteric small-molecule SARM1 inhibitor preventing axonal degeneration
Phase 1, Small molecule, NAD+ metabolism, SARM1
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Funding rounds and grants3
- People10
- Signals2
- Similar companies6